In this study, we examined the effects of organic types of calcium derived from oyster shell (OS-Ca) and nano-calcium (Nano-Ca) on the bio-availability and physiological responses associated with bone health in ovariectomised rats. Increased body weight, which is one of the physiological effects of ovary removal, was significantly recovered by Nano-Ca treatment (p<0.05). The reduced calcium level in the liver in ovariectomised rat was increased significantly with OS-Ca and Nano-Ca treatment (p<0.05), suggesting improved calcium bio-availability. Alkaline phosphatase (ALP), osteocalcin, and deoxypyridinoline (DPD) were analysed as biochemical markers of bone metabolism and health in the presence or absence of OSCa and Nano-Ca. ALP, osteocalcin, and DPD levels increased following ovary removal and tended to decrease after treatment with Nano-Ca, indicating that Nano-Ca induces favourable bone metabolism. This result was reflected in the recovery of bone mineral density (BMD) and bone mineral content (BMC) of the femur after Nano-Ca treatment following ovary removal. Taken together, our data show that the tested calcium treatments, especially using Nano-Ca, enhanced the bioavailability or absorption of calcium and positively affected bone metabolism in ovariectomised rats.
Introduction
Calcium is one of the most important minerals that regulates various physiological responses at the tissue and cellular levels. It plays an important role in a formation of bone, muscle contraction, coagulation, enzymatic activation, penetration of cell membranes etc. Nearly all (99%) of the calcium in the body is stored in the bones and teeth, where it has structural and functional roles, respectively (Ross et al., 2011) . The remainder of the body's calcium is crucial to physiological functions, such as nerve transmission and intracellular signalling (Ross et al., 2011) .
Calcium is not synthesised in human body; it must be absorbed via food. When sufficient amounts are not supplied, calcium is released from bone over time, which can cause fragile bone structure. Bone mass is constantly maintained through a continuing processes of bone formation by osteoblasts and bone resorption by osteoclasts (Datta et al., 2008) . The bone remodelling process undergoes changes with age. In childhood, there is more bone formation than resorption; whereas in middle adulthood, both processes are maintained equally. However, at older ages, notably in postmenopausal women, bone resorption exceeds formation, leading to bone loss and lower bone density. Calcium imbalance due to dominant resorption over time results in increased risk of bone diseases such as osteoporosis (Datta et al., 2008; Jackson et al., 2006) . Osteoporosis is a condition that induces reduced bone density and an enhanced risk of fracture (Datta et al., 2008) . The reduction of bone density originates from an excessive loss of bone components and/or insufficient bone formation. It is closely related to reduced calcium intake and a hormone (oestrogen) deficiency (Prentice, 2004) . Although lack of oestrogen is a major factor in osteoporosis, a shortage of calcium intake over time also significantly contributes to the occurrence of osteoporosis (Jackson et al., 2006; Prentice, 2004) . The sufficient calcium intake in adulthood can help prevent osteoporosis (Prentice, 2004).
However, it is difficult to maintain an optimal calcium intake level in present-day life. Thus, calcium supplements are suggested as an alternative (Straub, 2007) . In fact, the utility of a calcium supplement varies in terms of the availability of calcium in the body, which depends on the In this study, we investigated organic calcium materials as sources of calcium supplements for the prevention and treatment of osteoporosis, expecting enhanced bio-availability and favourable bone metabolism based on increased solubility in the body. Our study evaluated the effect of oyster shell calcium (OS-Ca) and nano-calcium (NanoCa) on bio-availability and physiological functions using rats with osteoporosis induced by ovary removal and a lowcalcium diet.
Materials and Methods

Materials
Nanonised oyster shell calcium (Nano-Ca) and micronised oyster shell calcium (OS-Ca) were prepared at Apexel Co. Ltd. (Korea) by a novel dry cryo-nanonisation grinding system integrated with a size separator. All reagents and standard solutions used in this study were of reagent grade from Sigma Chemical Co. (USA).
Animals and treatments
Female Sprague-Dawley (SD, 10-wk-old) rats were obtained from Deahan Biolink Co. Ltd. (Korea). Animals were maintained in 42×28 cm cages at 22-24 o C and a humidity of 60±5%, and the day and night cycle was automatically controlled in the animal house at Korea University. Food and deionised water were supplied ad libitum. The body weight and amount of intake were measured every 7 d. After acclimatisation for 1 wk, female SD rats were anesthetised with 2% isoflurane, and the ovaries were removed bilaterally (Murray, 1936) . The ovaries were removed when the average body weight was approximately 250.7±5 g. For the Sham group, an abdominal operation was performed without ovary removal. Animals were grouped by random sampling selection with 8 rats per group in a total of 4 groups, as follows: normal control group (normal calcium diet after mock-operation, Sham), ovariectomy control group (low calcium diet after ovariectomy, OVX-C), OS-Ca treatment group (low calcium diet with OS-Ca after ovariectomy, OVX + OS-Ca), and Nano-Ca treatment group (low calcium diet with Nano-Ca after ovariectomy, OVX + Nano-Ca). OA-Ca or Nano-Ca was administered at 40 mg/d in 1 mL saline for 4 wk. Table 1 shows the experimental groups in this study. A purified diet based on the AIG-93 formula was prepared (Table 2) . CaCl 2 was purchased from Samchun Chemical Co. Ltd. (Korea). The vitamin mixture (AIN-93-VX) was obtained from Deahan Biolink Co. Ltd. The mineral mix was prepared as AIN-93G-MX-calcium free and was obtained from Deahan Biolink Co. Ltd.
Sample collection
Animals were sacrificed by etherisation after fasting for 12 h. Blood was collected from the aorta. Serum was obtained from supernatant of the blood after centrifugation at 3,000 g at 4 o C, and stored at -70 o C until analysis. Organs such as the liver, kidney and spleen, and femur were harvested and cleaned with 0.9% NaCl. Their weights were measured after the elimination of attached fat, muscle, and water. The weight of the organs was expressed as a relative ratio to 100 g of body weight. 
Biochemical assays
Serum and liver were pre-treated using the wet digestion method. Briefly, 0.25 g (1 mL) of samples was digested at 100 o C for 10 h in the presence of 5 mL 65% HNO 3 . Calcium in the serum and liver was analysed using an Optima 2100 DV ICP-OES (PerkinElmer, USA). All equipment was cleaned with 2% nitric acid for 12 h and rinsed with distilled water prior to use. Alkaline phosphatase (ALP) and creatine were measured using a FUJI DRI-CHEM 3500 (Fuji Photo Film Co., Japan) and automatic chemical analyser. Osteocalcin and deoxypyridinoline (DPD) were analysed using a rat osteocalcin ELISA kit (R&D Systems Inc., USA) and rat DPD ELISA kit (R&D Systems Inc.), respectively. The mineral density and calcium content in the femur were analysed using dual energy X-ray absorptiometry (DEXA, PIXImus, USA).
Statistical analysis
All statistical analyses, including standard error of mean (SEM), were performed using the Statistical Package for Social Sciences version 12.0 (SPSS Inc., USA). The statistical significance of differences was determined using an ANOVA, and detailed post-verification was performed by Duncan's multiple range test at a significance level of p<0.05.
Results and Discussion
Body weight and food intake We examined the effects of calcium treatments on food intake and body weight (Fig. 1) . Body weight was shown to increase significantly in the ovariectomy groups compared with the Sham group (p<0.05). The increased weight in ovariectomised groups was thought to be a climacteric symptom of ovary removal. Os-Ca treatment resulted in slightly lower body weight compared with the ovariectomised group (OVX-C), but the difference was not significant. In Nano-Ca treatment, body weight was significantly decreased compared to the ovariectomised group (OVX-C) (p<0.05), suggesting that Nano-Ca intake can improve a menopausal symptom derived from ovary removal.
This result correlates with other studies, which showed a relationship between calcium intake and body weight (Jacqmain et al., 2003; Zemel, 2002) . Food intake was shown to increase in ovariectomised groups compared with the Sham group. In particular, the Os-Ca-treated group (23.22 g/d) showed a significant increase in daily food Ovary removal reduces the levels of oestrogen, a sex hormone, which plays an important role in the inhibition of adipocyte differentiation. Thus, oestrogen deficiency is thought to increase lipid accumulation by promoting adipocyte differentiation, contributing to increased body weight (Grün and Blumberg, 2009 ). However, Kalu et al. (1989) reported that increased body weight due to ovary removal resulted from increased food intake rather than an oestrogen shortage. In addition, numerous studies reported an increase in body weight due to low calcium intake (Zhao et al., 2011). Our data indicated that calcium intake via Os-Ca or Nano-Ca can ameliorate the increase in body weight caused by oestrogen deficiency.
Organ weight and calcium concentration
To determine whether the change in body weight after calcium treatment is connected to the weights of organs, we investigated the effects of calcium treatment on the weights of the liver, spleen, and kidney (Table 3 ). The weights of the liver and spleen were not significantly changed by ovary removal and calcium treatment. However, the kidney weight tended to decrease after ovary removal, but the administration of calcium did not affect its weight. In the ovary removal model, calcium intake results in weight changes in the organs. Lee et al. (2011) reported that low calcium intake after ovary removal significantly changes the weight of spleen. The calcium level in the blood did not show any significant difference among the experimental groups; the level was normal (7.2-13 mg/dL) in all groups (Fig. 2) . A number of studies showed no difference in the level of calcium in the blood when various levels of calcium supplements were administered to rats with osteoporosis (Choi, 1996; Hietala, 1993) . Calcium homeostasis is balanced by calcium metabolic hormones such as the parathyroid hormone and calcitonin (Mundy and Guise, 1999) .
The calcium level in the liver was decreased by ovary removal (Fig. 2) . However, OS-Ca or Nano-Ca treatment increased the liver calcium level in the ovariectomised groups, with the Nano-Ca group showing the highest increase. This result showed that the bio-availability and absorption of calcium depends on the type of calcium compound, specifically on the molecular weight of the compound.
The oral administration of nanonised pearl powder was found to result in better long-term absorption of calcium, higher gain in body weight, and higher gains in the weight and length of rat femurs than that micronised pearl powder (Cui et al. Bone metabolism markers bone mineral density (BMD) and bone mineral content (BMC) of the femur Bone remodelling constantly occurs in the body through bone formation by osteoblasts and bone resorption by osteoclasts. We examined effects of calcium treatment on bone formation markers such as ALP and osteocalcin (Fig.  3) . ALP, a biochemical marker for bone-forming activity, is associated with the mineralisation of osteoblasts. Many studies reported increased ALP activity in osteoporotic and ovariectomised patients (Arjmandi et al., 2000; Ostrowska  et al., 2002) . The other marker for bone turnover is osteocalcin. Osteocalcin contains a vitamin K-dependent γ-carboxyglutamic acid (Gla) residue responsible for calcium binding and is also involved in bone mineralisation. Osteocalcin is formed in osteoblasts and becomes trapped in the bone matrix. Some is released to blood and can be analysed. It is known to increase in abnormal bone metabolic conditions (Sikavitsas et al., 2001 ). The levels of ALP and osteocalcin tended to be higher in the ovariectomised group with a low calcium diet (OVX-C) compared with Sham group, suggesting that bone metabolic disorders occur after ovary removal. The OS-Ca and Nano-Ca groups showed improvement in the level of ALP and osteocalcin compared with the OVX-C group (Fig. 3) . The Nano-Ca group in particular showed a significant decrease in the osteocalcin level compared with the OVX-C group The DPD crosslinking value has been used as a marker for bone diseases, including osteoporosis. It is usually expressed as a ratio of DPD to creatinine. Most DPD levels are found in bone and cartilage. DPD in urine is known to be produced from bone resorption (Robins et al., 1994) . Thus, an increase in DPD represents an increase in bone resorption by activated osteoclasts, showing a negative correlation with bone density. In our data, the DPD excretion level was significantly increased by ovary removal (p<0.05), but Nano-Ca treatment restored DPD levels to normal (Fig. 4) .
We determined the effects of OS-Ca and Nano-Ca on the bone mineral density (BMD) and bone mineral content (BMC) of the femur (Fig. 5) . OS-Ca and Nano-Ca treatment significantly improved the BMD of the femur after ovary removal (p<0.05) (Fig. 5) . The BMC of the femur also decreased after ovary removal, but its level did not change after OS-Ca or Nano-Ca treatment. Menopausal osteoporosis exhibits bone metabolism in which bone absorption first occurs, followed by increased bone formation to achieve a balance. Oestrogen deficiency induces an increase in osteoclast activity and bone absorption by increasing bone turnover, eventually generating bone loss through decreased bone formation (Fanti et al., 1998) . Gao et al. (2008) reported that the absorption and utilisation of calcium in rats differs with different sizes of pearl powders. These results strongly support the favourable effect of the two sizes of pearl powders on absorption and utilisation of calcium and bone formation in rats. However, the absorption and utilisation of calcium and bone formation in rats that received nanometre-sized pearl powder was markedly better than that in rats that received micrometre pearl powder. This study therefore strongly suggests that smaller pearl powders could effectively reduce the difficulty of calcium release, increase absorption of calcium and maintain bone normal function in rats.
The above results indicate that the effect of mineral material particle sizes on digestibility and solubility is an important factor that affects their bioavailability. If mineral materials in the alimentary tract are insoluble, they cannot be absorbed. Therefore, when mineral materials are utilised to supply microelements, particle size is very important. Our results also showed Nano-Ca exhibited enhanced bio-availability or absorption of calcium and positively affected bone metabolism in ovariectomised rats.
